Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
respiratory syncytial virus virosome vaccine
- Development stage
- Preclinical
- Lead developer
- Mymetics
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The respiratory syncytial virus (RSV) virosome vaccine is a prophylactic biologic candidate developed by Mymetics BV for the prevention of RSV infection and associated lower respiratory tract disease. The vaccine utilizes a virosomal platform, which consists of reconstituted viral envelopes that serve as a delivery vehicle for the RSV fusion (F) and attachment (G) glycoproteins. A key feature of this candidate is its formulation with adjuvants, including monophosphoryl lipid A (MPLA) or 3D-PHAD (a synthetic MPLA) and TLR2 ligands such as Pam3CSK4. These adjuvants are specifically chosen to induce a Th1-biased immune response, which is intended to provide protective immunity while avoiding the Th2-biased response associated with vaccine-enhanced respiratory disease (VERD). The vaccine targets high-risk populations, including infants, young children, the elderly, and immunocompromised adults.
- Other names
- RSV virosome vaccineMymetics RSV vaccine
02
Targets
RSV F (Respiratory syncytial virus fusion protein)RSV G (Respiratory syncytial virus attachment glycoprotein)TLR4 (Toll-like receptor 4)TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on respiratory syncytial virus virosome vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on respiratory syncytial virus virosome vaccine.